Form 4: Equillium Director Receives Stock Option Grant

Director Barbara Troupin was granted 70,000 stock options in Equillium, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Barbara Troupin received a grant of 70,000 stock options for Equillium, Inc. (EQ) common stock.
• The options have an exercise price of $2.84 per share.
• The grant date for these options is May 28, 2026.
• The options are set to expire on May 27, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant signal regarding company performance.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility could impact the value of the options, potentially affecting director retention or incentive alignment.

Future Outlook

The options vest in twelve equal monthly installments starting May 28, 2026, with full vesting guaranteed by the date of the next annual stockholders meeting.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The use of monthly vesting schedules for director options is consistent with standard practices for small-cap biotech firms.
• The ten-year expiration term is standard for executive and director stock option plans.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options in monthly installments.
• Potential exercise of options by the director after vesting.

Key Dates

Keywords

Equillium, EQ, Form 4, Stock Options, Insider Trading, Director Compensation